NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company") today announced that Anne Johnson, the Company's interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO).
Anne succeeds Stephen Bardin as the Company's CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition.
"Anne has been an integral member of our team for over three years and has demonstrated the executive leadership, financial acumen, and track record to lead our financial organization with excellence," said atai Co-founder and Chief Executive Officer, Florian Brand. "With her deep technical expertise and detailed knowledge of both the biopharmaceutical industry and atai's operating model, I look forward to working closely with her in her new position as we continue to execute our strategy. I also want to express my deepest gratitude to Stephen for his significant contributions to atai's mission."
Anne brings almost 20 years of biotechnology and pharmaceutical experience. She previously served in senior leadership roles at Aruvant Sciences, Inc., a Roivant company; Chimerix, Inc.; PPD; and Xanodyne Pharmaceuticals. Anne received her Bachelor of Science in Accounting from the University ...